NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Have a look at this, hyperopia.

https://clincancerres.aacrjournals.org/content/clincanres/24/16/3845.full.pdf

It's probably the best available description of Direct methodology.
There are many differences between the production of Direct and the production of L and how each is administered. Differences include (but aren't limited to) degree of DC maturation, the differences in the constituents of the maturational cocktail and at what point in the process these agents are employed, site of injection, and site of antigen presentation. And a lot of the processes are proprietary anyway.
I certainly don't profess to have anything other than a very rudimentary understanding of the critical processes that are involved, and how precisely these processes differ between the two products.

Dr Bosch is probably the only individual that could give an in-depth description of the differences and similarities, and which distinctions are considered critical to the optimal efficacy of each.
We know that for Direct, Method B was considered a critical enhancement, using a different time frame to optimize the required partial DC maturation.

So, they are similar in terms of broad principles and mechanism of action, but considerably different in terms of precise detailed preparation and administration. And you could say that makes for very different products. The process is the product!

I'm sure they learned a lot from the PI, which they will employ in the P2's. Method B obviously, but other refinements including ensuring they isolate the highest functional DC precursors to start with. Plus, as we know, the injection of multiple tumors where indicated.